Analysis of a Novel Impurity in Compounded Tirzepatide-B12 Products

U.S. market samples of compounded tirzepatide and vitamin B12 combinations were tested using analytical methods. The research identified a widespread, previously unknown impurity resulting from a chemical reaction between the components. The dataset, authored by Brad Jordan and last updated in April 2026, highlights potential patient safety risks from untested drug combinations.

Use Cases

• Identifying chemical impurities in compounded pharmaceuticals based on the described mass spectrometry analysis.
• Assessing regulatory compliance gaps for drug compounding based on the described market availability of untested products.
• Evaluating patient safety risks from novel drug-impurity interactions based on the described chemical reaction findings.
• Benchmarking analytical methods for peptide-related impurity detection based on the described testing approach.

Strengths

• Dataset is openly licensed under CC-BY-4.0.
• Focus is on a specific, novel impurity identified in a described class of products.
• Platform tags provide clear domain classification for discovery.

Limitations

• Dataset size is 293.7 KB, indicating a very limited scope, likely a research article rather than a large data corpus.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare, authored by Brad Jordan.

Collection Method

Samples obtained from various U.S. market sources and tested using analytical methods.

Time Range

Publication date implied by last update in April 2026.

Freshness

Last updated 2026-04 30 07:20:55; freshness should be verified.

Geography

Samples sourced from the U.S. market.